Trial Profile
A Randomized, Double Blind Placebo Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZYGK1, a Novel Glucokinase Activator, Following Oral Administration in Healthy Volunteers
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs ZY GK1 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Zydus Lifesciences
- 29 Jan 2014 Planned End Date changed from 1 Sep 2012 to 1 Apr 2014 as reported by ClinicalTrials.gov record.
- 29 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 18 Jan 2012 New source identified and integrated (Clinical Trials Registry - India; CTRI2011-12-002249).